The notice from Nasdaq regarding the late filing and the need to restate financial statements could negatively impact investor confidence in Ocean Biomedical. This may lead to a short-term decline in the stock price as investors may perceive the restatement as a sign of potential issues with the company's financial controls or accuracy of reported results. The requirement to submit a compliance plan adds to the uncertainty.